Sareum share price plummets ahead of AGM

The likelihood that specialist cancer drug discovery business Sareum will conclude a deal to commercialise a research programme this year has fallen, according to an announcement made ahead of its annual general meeting on Wednesday morning.

The likelihood that specialist cancer drug discovery business Sareum will conclude a deal to commercialise a research programme this year has fallen, according to an announcement made ahead of its annual general meeting on Wednesday morning.

During the AGM, Dr. Paul Harper, the company's Chairman, is expected to say: "Sareum has made good progress during the year in a number of key areas and we continue to focus on commercialising our research programmes to fund the future growth of the company.

"Although collaboration and licensing discussions around a number of programmes continue, it has become increasingly apparent that the opportunity of concluding such a deal before the calendar year-end is now less likely than the board had previously anticipated.

"However, the board remains confident that a commercial deal with one or more of its programmes will be concluded. We remain focused on maximising the opportunities for commercial exploitation however they arise."

Dr Harper added: "The addition of the £4m SEDA financing facility, from which the first tranche of funding was drawn down last week, gives us considerable flexibility in funding further development work, as well as putting us in a strong position to negotiate with collaborators and possible partners."

Sareum's share price was down 20.29% to 1.38p at 09:56 on Wednesday morning.

MF

Recommended

A new legal headache for Haleon
Stocks and shares

A new legal headache for Haleon

Haleon, GSK’s former consumer-products arm, spun off last month, has made a dismal debut on the stockmarket.
17 Aug 2022
Persimmon yields 12.3%, but can you trust it to deliver?
Share tips

Persimmon yields 12.3%, but can you trust it to deliver?

With a dividend yield of 12.3%, Persimmon looks like a highly attractive prospect for income investors. But that sort of yield can also indicate compa…
17 Aug 2022
Cineworld faces a bleak future – investors should stay away
Share tips

Cineworld faces a bleak future – investors should stay away

Weighed down by crippling debts and with consumers tightening their belts, Cineworld's future does not look bright, says Rupert Hargreaves. Investors …
17 Aug 2022
Britain’s ten most-hated shares – w/e 12 August
Stocks and shares

Britain’s ten most-hated shares – w/e 12 August

Rupert Hargreaves looks at Britain's ten most-hated shares, and what short-sellers are looking at now.
16 Aug 2022

Most Popular

Don’t listen to the doom-mongers – the future is bright
Economy

Don’t listen to the doom-mongers – the future is bright

With volatile markets, raging inflation and industrial unrest, it may feel like things are bad and likely to get worse. But the end of the world is no…
15 Aug 2022
Investors should get ready for a political revolution
UK Economy

Investors should get ready for a political revolution

Liz Truss will beat Rishi Sunak, cut taxes, and then shake up the Bank of England, says Helen Thomas
15 Aug 2022
How solar panels could lower your energy bill
Energy

How solar panels could lower your energy bill

Solar-panel installation firms are reporting a four-fold increase in orders this year compared with 2021. Ruth Jackson-Kirby explains how solar can he…
14 Aug 2022